Compare AbCellera Biologics Inc (ABCL) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Gold Fields Limited — how do they compare? AbCellera Biologics Inc trades at $9.21 (market cap $2.99B), while Gold Fields Limited trades at $42.43 (market cap $36.07B). The key difference: Gold Fields Limited is far larger — about 12.1× AbCellera Biologics Inc's market cap, and Gold Fields Limited pays a 5.76% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GFI | |
|---|---|---|
Market Cap | $2.99B | $36.07B |
Sector | Health | Basic Materials |
52-Week High | $9.76 | $61.52 |
52-Week Low | $2.78 | $29.31 |
Enterprise Value | $2.58B | $37.51B |
Dividend Yield | — | 5.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Gold Fields Limited (GFI) trades at $41.12, up 0.73% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 40.76% net income margin and ROE of 52.33%, though recent quarterly earnings missed expectations. Revenue grew to $5.2B in 2024, with net income reaching $1.25B. Analyst consensus is a Buy with a $52 price target, indicating 26% upside potential.
The outlook for GFI is positive given its robust fundamentals and gold price tailwinds, but risks include volatile earnings performance and rising debt levels. Institutional accumulation and favorable sector sentiment support the bullish case, though investors should monitor cost pressures and execution on growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
